<?xml version="1.0" encoding="UTF-8"?>
<ref id="B29-vaccines-08-00197">
 <label>29.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ramirez</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Morris</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Maucourant</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Dâ€™Ascanio</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Crescente</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Lu</surname>
    <given-names>I.-N.</given-names>
   </name>
   <name>
    <surname>Farinelle</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Muller</surname>
    <given-names>C.P.</given-names>
   </name>
   <name>
    <surname>Whelan</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Rosenberg</surname>
    <given-names>W.</given-names>
   </name>
  </person-group>
  <article-title>A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles</article-title>
  <source>Vaccine</source>
  <year>2018</year>
  <volume>36</volume>
  <fpage>873</fpage>
  <lpage>880</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.12.053</pub-id>
  <pub-id pub-id-type="pmid">29306508</pub-id>
 </element-citation>
</ref>
